SGEN Seattle Genetics Inc

Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada.

$169.50  -3.70 (-2.14%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/07/2001
Outstanding shares:  182,855,795
Average volume:  735,296
Market cap:   $31,670,623,694
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    81181C104
ISIN:        US81181C1045
Sedol:      BLPK4D2
Valuation   (See tab for details)
PE ratio:   -93.15
PB ratio:   9.79
PS ratio:   18.14
Return on equity:   -10.51%
Net income %:   -19.06%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy